We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris (VTRS) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Viatris (VTRS - Free Report) closed at $9.36, marking a +0.32% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.04%. Elsewhere, the Dow lost 0.14%, while the tech-heavy Nasdaq added 2.14%.
Coming into today, shares of the generic drugmaker had lost 3.01% in the past month. In that same time, the Medical sector gained 3.53%, while the S&P 500 gained 5.1%.
Viatris will be looking to display strength as it nears its next earnings release, which is expected to be May 8, 2023. The company is expected to report EPS of $0.70, down 24.73% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $3.79 billion, down 9.48% from the prior-year quarter.
VTRS's full-year Zacks Consensus Estimates are calling for earnings of $2.95 per share and revenue of $15.71 billion. These results would represent year-over-year changes of -12.2% and -3.38%, respectively.
Investors should also note any recent changes to analyst estimates for Viatris. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.47% higher within the past month. Viatris currently has a Zacks Rank of #4 (Sell).
Looking at its valuation, Viatris is holding a Forward P/E ratio of 3.17. This represents a discount compared to its industry's average Forward P/E of 19.72.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 166, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris (VTRS) Gains As Market Dips: What You Should Know
In the latest trading session, Viatris (VTRS - Free Report) closed at $9.36, marking a +0.32% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.04%. Elsewhere, the Dow lost 0.14%, while the tech-heavy Nasdaq added 2.14%.
Coming into today, shares of the generic drugmaker had lost 3.01% in the past month. In that same time, the Medical sector gained 3.53%, while the S&P 500 gained 5.1%.
Viatris will be looking to display strength as it nears its next earnings release, which is expected to be May 8, 2023. The company is expected to report EPS of $0.70, down 24.73% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $3.79 billion, down 9.48% from the prior-year quarter.
VTRS's full-year Zacks Consensus Estimates are calling for earnings of $2.95 per share and revenue of $15.71 billion. These results would represent year-over-year changes of -12.2% and -3.38%, respectively.
Investors should also note any recent changes to analyst estimates for Viatris. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.47% higher within the past month. Viatris currently has a Zacks Rank of #4 (Sell).
Looking at its valuation, Viatris is holding a Forward P/E ratio of 3.17. This represents a discount compared to its industry's average Forward P/E of 19.72.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 166, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.